Immuron Limited (AU:IMC)
ASX:IMC
Want to see AU:IMC full AI Analyst Report?
IMC Stock Chart & Stats
AU$0.04
<AU$0.01(3.80%)
At close: 4:00 PM EST
AU$0.04
<AU$0.01(3.80%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.10
Previous CloseN/A
Volume128.40K
Average Volume (3M)862.36K
Market Cap
AU$9.15M
Enterprise Value-AU$971.34K
Total Cash (Recent Filing)AU$10.00M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Aug 28, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding326,653,600
10 Day Avg. Volume372,599
30 Day Avg. Volume862,359
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.75
Price to Sales (P/S)1.93
P/FCF Ratio-2.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$9.70M
Bulls Say, Bears Say
Bulls Say
Commercial Product And Oral Immunotherapy PlatformHaving an FDA/marketed-style commercial product (Travelan) proves Immuron can manufacture, distribute and monetize an oral immunotherapy. This provides a recurring revenue base, established channels and a platform that can be leveraged for additional gut-targeted products and partnerships over time.
Positive Revenue Growth TrendConsistent mid-teens revenue growth indicates sustained market demand for the company’s product(s) and early commercial traction. Over 2–6 months this supports continued top-line expansion, easier partner discussions, and a clearer path to scale if operational losses are addressed.
Conservative Leverage (very Low Debt)Very low financial leverage reduces solvency and interest-rate risks and preserves financing optionality. For a clinical-stage biotech, this financial conservatism supports resilience through volatile development cycles and gives management flexibility to pursue partnerships or raise capital with limited debt burden.
Bears Say
Ongoing Negative Profitability And MarginsPersistent negative EBIT and net profit show the business has not yet achieved operational breakeven. Over the medium term this limits internal funding for R&D and commercialization, raises reliance on external capital, and increases dilution or restructuring risk if margins don't improve.
Negative Operating And Free Cash FlowNegative operating and free cash flow mean the company burns cash to run operations and cannot self-fund growth or trials. This durable constraint forces ongoing capital raises or partnerships, increases execution risk for pipeline programs, and can delay commercialization plans.
Revenue Concentration And Clinical/regulatory DependencyMaterial reliance on a single marketed product and future pipeline outcomes creates structural revenue concentration. Long-term growth depends on clinical successes and approvals, which are uncertain and can take years, making revenue durability and scaling contingent on binary regulatory events.
Immuron Limited News
IMC FAQ
What was Immuron Limited’s price range in the past 12 months?
Immuron Limited lowest share price was AU$0.03 and its highest was AU$0.10 in the past 12 months.
What is Immuron Limited’s market cap?
Immuron Limited’s market cap is AU$9.15M.
When is Immuron Limited’s upcoming earnings report date?
Immuron Limited’s upcoming earnings report date is Aug 28, 2026 which is in 131 days.
How were Immuron Limited’s earnings last quarter?
Immuron Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of AU$0 by -AU$0.007.
Is Immuron Limited overvalued?
According to Wall Street analysts Immuron Limited’s price is currently Overvalued.
Does Immuron Limited pay dividends?
Immuron Limited does not currently pay dividends.
What is Immuron Limited’s EPS estimate?
Immuron Limited’s EPS estimate is 0.
How many shares outstanding does Immuron Limited have?
Immuron Limited has 326,653,600 shares outstanding.
What happened to Immuron Limited’s price movement after its last earnings report?
Immuron Limited reported an EPS of -AU$0.007 in its last earnings report, missing expectations of AU$0. Following the earnings report the stock price went up 14.286%.
Which hedge fund is a major shareholder of Immuron Limited?
Currently, no hedge funds are holding shares in AU:IMC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immuron Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IMC Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.20%
12-Months-Change
Fundamentals
Return on Equity
-43.95%
Trailing 12-Months
Asset Growth
18.12%
Trailing 12-Months
Company Description
Immuron Limited
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers' diarrhea in the United States, and Phase II field trial for Travelers' Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Technical Analysis
Noxopharm Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Anatara Lifesciences Ltd
―
Neuroscientific Biopharmaceuticals Ltd.
―